Clinical-stage global biopharmaceutical company Structure Therapeutics ( NASDAQ: GPCR ) said that Blai Coll, M.D., Ph.
D., has been promoted to Chief Medical Officer, replacing Mark Bach, M.D.
, Ph.D. as part of a planned succession, effective September 18.
Dr. Coll has served as VP of Clinical Development at Structure since 2022. In addition, Ashley Hall, J.
D., has been appointed to the newly created position of Chief Development Officer. More on Structure Therapeutics Structure Therapeutics: Pay Attention To This Overlooked Player In GLP-1 Weight Loss Field Seeking Alpha’s Quant Rating on Structure Therapeutics Historical earnings data for Structure Therapeutics Financial information for Structure Therapeutics.
